New Acting Chief Executive appointed

Other News // 2nd December 2021

Myeloma UK is delighted to share the news that Jo Nove, Director of Communications & Brand, has been appointed as Acting Chief Executive.

This announcement comes as current Chief Executive Laura Kerby moves on to lead Prostate Cancer UK, a charity close to her heart after her father was diagnosed with the disease four years ago. Jo will work alongside Laura until her departure in February and will then lead the charity until a permanent Chief Executive is appointed.

Simon Linnett, Chairman of Myeloma UK’s Board of Trustees said:

“As a leading blood cancer charity, we more than understand the impact of cancer on families and we understand Laura’s very personal decision to take the helm at Prostate Cancer UK. We’ll be sad to see her go and would like to thank her for all her work on behalf of patients and her unflagging dedication to improving the lives of those affected by myeloma. Ahead of her departure, we’re very pleased to announce that our Director of Communications & Brand, Jo Nove, will take on the role of Acting Chief Executive. The Board felt it was important to appoint an Acting Chief Executive from the current Executive Leadership Team to ensure we maintained momentum behind the delivery of Myeloma UK’s long-term goals and plans. Regarding the permanent appointment, the Board has already begun work on recruitment to ensure that the charity can move forward in the longer term with a CEO of the highest standard. The work that the Executive Leadership Team has undertaken to refresh our strategy in recent months means Myeloma UK will continue to be mission-driven and put patients, families and carers at the heart of everything that we do.”

Acting Chief Executive Jo Nove said:

“2021 has been yet another challenging year for the myeloma community and, as we continue to move through the pandemic, we must make sure their voices continue to be heard. Equally, we cannot let COVID-19 curtail our future ambitions for potential new treatments, improvements to diagnosis and research. All the staff at Myeloma UK are focused and ready to meet the challenges of 2022.”

Commenting on her departure, outgoing Chief Executive Laura Kerby said:

“When I arrived at Myeloma UK, I was very fortunate to inherit a charity which had already made a huge impact on the lives of patients and their families and one which was already weathering the storm of the pandemic by keeping patients at the heart of everything they did. It has been a privilege to work with such a dedicated Executive Team and a group of highly committed and proactive staff. We have strategic goals and plans in place and I am confident these will be delivered by Jo and the Executive Team.”